Nexalin Technology, INC. (NXL) — SEC Filings

Overview

Nexalin Technology, INC. (NXL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: Nexalin Technology, Inc. (NXL) reported a challenging fiscal year ended December 31, 2025, with significant operating losses and a going concern warning from its independent auditor. The company's revenue from its Gen-1 devices, which are FDA-cleared for anxiety and insomnia but not for new sales in

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 6 bearish, 39 neutral. The dominant filing sentiment for Nexalin Technology, INC. is neutral.

Filing Type Overview

Nexalin Technology, INC. (NXL) has filed 3 10-K, 24 8-K, 6 10-Q, 2 10-K/A, 3 DEF 14A, 5 S-1/A, 2 S-1 with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• Nexalin Faces Delisting Risk Amidst Going Concern Warning, New Device Push — 10-K · Mar 25, 2026 Risk: high
  Nexalin Technology, Inc. (NXL) reported a challenging fiscal year ended December 31, 2025, with significant operating losses and a going concern warning from it
• 8-K Filing — 8-K · Dec 5, 2025
• Nexalin's Losses Widen Amid Revenue Dip, FDA Q-Sub Accepted — 10-Q · Nov 14, 2025 Risk: high
  Nexalin Technology, Inc. (NXL) reported a net loss of $2,276,311 for the three months ended September 30, 2025, compared to a net loss of $2,448,257 for the sam
• Nexalin Technology Files 8-K — 8-K · Oct 15, 2025 Risk: low
  Nexalin Technology, Inc. filed an 8-K on October 15, 2025, reporting an entry into a material definitive agreement and financial statements. The filing details
• Nexalin Amends 10-K for Control Weaknesses, Refiles 2024 Financials — 10-K/A · Sep 23, 2025 Risk: high
  Nexalin Technology, Inc. (NXL) filed a 10-K/A Amendment No. 2 on September 23, 2025, primarily to correct wording in Management's Report on Internal Control ove
• Nexalin Technology Files 8-K — 8-K · Sep 22, 2025 Risk: low
  Nexalin Technology, Inc. filed an 8-K on September 22, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
• Nexalin's Net Loss Widens 25% Amid Zero Revenue in Q2 — 10-Q · Aug 6, 2025 Risk: high
  Nexalin Technology, Inc. reported no revenue for the six months ended June 30, 2025, consistent with the prior year period. The company incurred a net loss of $
• Nexalin Technology Reports Officer Changes and Financials — 8-K · Aug 4, 2025 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on August 4, 2025, reporting events as of August 1, 2025. The filing pertains to the departure of directors or certain off
• Nexalin Technology Reports Officer/Director Changes & Compensatory Arrangements — 8-K · Jul 21, 2025 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on July 21, 2025, reporting events as of July 17, 2025. The filing pertains to the departure of directors or certain offic
• Nexalin Technology Files 8-K on Shareholder Vote Matters — 8-K · Jul 17, 2025 Risk: low
  Nexalin Technology, Inc. filed an 8-K on July 17, 2025, reporting on a submission of matters to a vote of security holders. The filing indicates that the compan
• Nexalin Sets July 15 Virtual Shareholder Meeting for Director Elections, Equity Plan Vote — DEF 14A · Jun 17, 2025 Risk: medium
  Nexalin Technology, Inc. (NXL) is holding its Annual Meeting of Stockholders on July 15, 2025, at 10:00 a.m. EST, virtually via https://www.cstproxy.com/nexalin
• Nexalin Technology Files 8-K — 8-K · Jun 9, 2025 Risk: low
  Nexalin Technology, Inc. filed an 8-K on June 9, 2025, reporting an event that occurred on June 6, 2025. The filing primarily concerns financial statements and
• Nexalin Technology Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: low
  Nexalin Technology, Inc. filed its 10-Q for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025 and comparative p
• Nexalin Technology Files 8-K for Material Agreement — 8-K · May 6, 2025 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on May 4, 2025, reporting the entry into a material definitive agreement. The filing also includes other events and financ
• Nexalin Technology Files 8-K — 8-K · May 5, 2025 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on May 5, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhibits. The
• Nexalin Technology Files 8-K: Accountant Change Reported — 8-K · Apr 17, 2025 Risk: low
  Nexalin Technology, Inc. filed an 8-K on April 17, 2025, reporting changes in its certifying accountant as of April 16, 2025. The filing also includes financial
• Nexalin Technology Files 2024 Annual Report Amendment — 10-K/A · Apr 15, 2025 Risk: medium
  Nexalin Technology, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing was made on April 15, 2025, an
• Nexalin Technology Files 2024 10-K — 10-K · Mar 14, 2025 Risk: medium
  Nexalin Technology, Inc. filed its 2024 10-K on March 14, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Houston, TX, operat
• Nexalin Technology Files 8-K — 8-K · Feb 6, 2025 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on February 6, 2025, reporting an event on February 3, 2025. The filing is a current report under the Securities Exchange
• Nexalin Technology Files S-1/A Amendment — S-1/A · Jan 30, 2025 Risk: medium
  Nexalin Technology, Inc. filed an S-1/A amendment on January 30, 2025, for its registration statement. The company, incorporated in Delaware with its principal
• Nexalin Technology Files S-1/A Amendment — S-1/A · Jan 10, 2025 Risk: medium
  Nexalin Technology, Inc. filed an S-1/A amendment on January 10, 2025, for its registration statement. The company, incorporated in Delaware with its principal
• Nexalin Technology Files S-1 for Public Offering — S-1 · Dec 20, 2024 Risk: medium
  Nexalin Technology, Inc., a Delaware-based company specializing in electromedical apparatus, filed an S-1 registration statement on December 20, 2024. The compa
• Nexalin Technology Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Nexalin Technology, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position, including
• Nexalin Technology Files 8-K — 8-K · Nov 1, 2024 Risk: low
  Nexalin Technology, Inc. filed an 8-K on November 1, 2024, reporting other events and financial statements. The filing details the company's incorporation in De
• Nexalin Technology Faces Delisting Concerns — 8-K · Sep 25, 2024 Risk: high
  Nexalin Technology, Inc. filed an 8-K on September 25, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event
• Nexalin Technology Files 8-K on Leadership Changes & Financials — 8-K · Sep 19, 2024 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on September 19, 2024, reporting on the departure of directors, election of directors, appointment of officers, and compen
• Nexalin Technology Files 8-K on Security Holder Vote Matters — 8-K · Sep 3, 2024 Risk: low
  Nexalin Technology, Inc. filed an 8-K on August 26, 2024, reporting on the submission of matters to a vote of its security holders. The filing details the compa
• Nexalin Technology Files 10-Q for Q2 2024 — 10-Q · Aug 8, 2024 Risk: medium
  Nexalin Technology, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second qua
• Nexalin Technology Appoints New CEO, Directors, and Adjusts Compensation — 8-K · Jul 30, 2024 Risk: medium
  Nexalin Technology, Inc. announced on July 29, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new dir
• Nexalin Technology Files Definitive Proxy Statement — DEF 14A · Jul 29, 2024 Risk: low
  Nexalin Technology, Inc. filed a Definitive Proxy Statement (DEF 14A) on July 29, 2024, for its annual meeting on August 26, 2024. The company, headquartered in
• Nexalin Technology Files 8-K Report — 8-K · Jul 16, 2024 Risk: low
  On July 16, 2024, Nexalin Technology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or financ
• Nexalin Technology Files 8-K: Material Agreement & Other Events — 8-K · Jul 3, 2024 Risk: medium
  On July 2, 2024, Nexalin Technology, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company
• Nexalin Technology Enters Material Definitive Agreement — 8-K · Jun 28, 2024 Risk: medium
  Nexalin Technology, Inc. entered into a Material Definitive Agreement on June 27, 2024, related to its business operations. The filing also includes other event
• Nexalin Technology Files S-1/A Amendment — S-1/A · Jun 26, 2024 Risk: medium
  Nexalin Technology, Inc. filed a Pre-Effective Amendment No. 3 to its Form S-1 Registration Statement on June 26, 2024. The company, incorporated in Delaware wi
• Nexalin Technology Files S-1/A Amendment — S-1/A · Jun 24, 2024 Risk: medium
  Nexalin Technology, Inc. filed an S-1/A amendment on June 24, 2024, for its registration statement (No. 333-279684). The company, incorporated in Delaware with
• Nexalin Technology Files 8-K — 8-K · Jun 18, 2024 Risk: medium
  Nexalin Technology, Inc. filed an 8-K on June 18, 2024, reporting an event that occurred on June 13, 2024. The filing pertains to "Other Events" and "Financial
• Nexalin Technology Files S-1/A Amendment — S-1/A · Jun 14, 2024 Risk: medium
  Nexalin Technology, Inc. filed an S-1/A amendment on June 14, 2024, for its initial public offering. The company, incorporated in Delaware with its principal ex
• Nexalin Technology Files S-1 Registration — S-1 · May 23, 2024 Risk: medium
  Nexalin Technology, Inc., incorporated in Delaware, filed an S-1 registration statement on May 23, 2024. The company, operating in the electromedical and electr
• Nexalin Technology Faces Delisting Notice — 8-K · May 21, 2024 Risk: high
  Nexalin Technology, Inc. filed an 8-K on May 21, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of May 16,
• Nexalin Technology, Inc. Files 10-Q for Q1 2024 — 10-Q · May 10, 2024 Risk: low
  Nexalin Technology, Inc. (NXL) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Nexalin Technology, Inc. filed a 10-Q report for the period ending
• Nexalin Technology Files 8-K — 8-K · Apr 26, 2024 Risk: low
  Nexalin Technology, Inc. filed an 8-K on April 26, 2024, reporting events as of April 25, 2024. The filing primarily concerns financial statements and exhibits,
• Nexalin Technology Files 8-K — 8-K · Apr 11, 2024 Risk: low
  Nexalin Technology, Inc. filed an 8-K on April 10, 2024, reporting other events and financial statements. The filing details the company's incorporation in Dela
• Nexalin Technology, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024 Risk: medium
  Nexalin Technology, Inc. (NXL) filed a Annual Report (10-K) with the SEC on March 27, 2024. Nexalin Technology, Inc. filed its 2023 Form 10-K on March 27, 2024.
• Nexalin Technology Holds Shareholder Vote — 8-K · Mar 20, 2024 Risk: low
  Nexalin Technology, Inc. filed an 8-K on March 20, 2024, reporting a shareholder meeting held on March 7, 2024. The primary purpose of the meeting was for secur
• Nexalin Technology, Inc. Announces Special Meeting of Stockholders on March 7, 2024 — DEF 14A · Jan 17, 2024 Risk:
  Nexalin Technology, Inc. (NXL) filed a Proxy Statement (DEF 14A) with the SEC on January 17, 2024. Nexalin Technology, Inc. will hold a Special Meeting of Stock

Risk Profile

Risk Assessment: Of NXL's 43 recent filings, 6 were flagged as high-risk, 23 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Nexalin Technology, INC.'s most recent 10-K filing (Mar 25, 2026):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Houston, TX
• Mark White
• Justin Van Fleet
• Martin S. Siegel
• Martin S. Siegel, Esq.
• Dr. Jianhua Wang
• Mr. Jianjun Li
• Andrew M. Tucker, Esq.
• Andrew M. Tucker

Industry Context

The mental health technology market is experiencing significant growth, driven by increasing awareness of mental health issues and demand for non-pharmacological treatments. Nexalin operates in the neurostimulation segment, competing with established players and emerging companies developing innovative therapies. The regulatory landscape for medical devices, particularly those targeting neurological conditions, is complex and requires substantial investment in clinical validation and FDA approval.

Top Tags

sec-filing (11) · financials (10) · amendment (5) · registration (5) · material-agreement (4) · 8-K (4) · regulatory-filing (4) · corporate-governance (4) · 8-k (4) · 10-Q (4)

Key Numbers

• Market Value of Non-Affiliate Stock: $14.7M — As of June 30, 2025, indicating a small market capitalization.
• Shares Outstanding: 20.6M — As of March 23, 2026, showing the current share count.
• Nasdaq Minimum Bid Price: $1.00 — NXL is not in compliance, risking delisting.
• Gen-1 Waveform: 4 milliamps — Original device output, now reclassified by FDA.
• Gen-2/3 Waveform: 15 milliamps — New advanced waveform for SYNC and HALO devices, currently in Q-submission.
• FDA Reclassification Year: 2019 — Gen-1 devices reclassified, halting new U.S. sales for anxiety/insomnia and requiring Class III for depression.
• Planned Clinical Trial Year: 2026 — For Gen-3 HALO in U.S., Brazil, and China.
• Accumulated Deficit: $90.5M — as of September 30, 2025, indicating significant historical losses
• Loss from Operations: $5.8M — for the nine months ended September 30, 2025, widening from $4.8M in 2024
• Negative Cash Flow from Operations: $3.8M — for the nine months ended September 30, 2025, indicating cash burn
• Revenue: $18,149 — for the three months ended September 30, 2025, a decrease from $36,031 in 2024
• Total Operating Expenses: $6,067,122 — for the nine months ended September 30, 2025, an increase from $4,991,695 in 2024
• Common Stock Outstanding: 18,651,939 — as of November 13, 2025
• Working Capital Surplus: $4.5M — as of September 30, 2025, providing some short-term liquidity
• Market Value (Non-Affiliate): $10.2M — Aggregate market value of common stock held by non-affiliates as of June 30, 2024, indicating public float.

Related Companies

NXT

Frequently Asked Questions